Samsung Bioepis' Enbrel drug copy gets EU approval

January 17, 2016 2:00 AM

21 0

SEOUL Jan 17 Samsung Bioepis Co Ltd said on Sunday it had received European Commission approval for its copy of the blockbuster biotech arthritis drug Enbrel.

The drug, known scientifically as etanercept, will be sold in Europe by U.S. biotechnology group Biogen and rolled out gradually across all 28 European Union member states as well as Norway, Iceland and Liechtenstein, the South Korean company said in a statement.

Also read: Samsung offers phone upgrade programme for South Korea Note 7 customers

Read more

To category page